{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B&page=2",
    "query": {
      "intervention": "HEPLISAV-B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T08:12:46.690Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06537414",
      "title": "A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B Virus Infection",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Daplusiran/Tomligisiran Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "Daplusiran/Tomligisiran Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "Bepirovirsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 283,
      "start_date": "2024-11-11",
      "completion_date": "2030-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06537414"
    },
    {
      "nct_id": "NCT01182311",
      "title": "Duration of Long-term Immunity After Hepatitis B Virus Immunization",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2010-09-08",
      "completion_date": "2020-12-09",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182311"
    },
    {
      "nct_id": "NCT04456504",
      "title": "HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthcare Worker, Hepatitis B Vaccine, Nonresponder"
      ],
      "interventions": [
        {
          "name": "Recombinant hepatitis B vaccine with CpG adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-09-15",
      "completion_date": "2023-12-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-16",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04456504"
    },
    {
      "nct_id": "NCT04804072",
      "title": "INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Drug Use",
        "Opioid Use",
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)",
          "type": "DRUG"
        },
        {
          "name": "HIV testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "HIV treatment for participants living with HIV not already in care",
          "type": "DRUG"
        },
        {
          "name": "PrEP for participants without HIV",
          "type": "DRUG"
        },
        {
          "name": "Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Testing and referral for treatment for hepatitis C virus (HCV)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Sexually transmitted infection (STI) testing and treatment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Primary care",
          "type": "OTHER"
        },
        {
          "name": "Harm reduction services",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Peer navigation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "COVID-19 testing and referral for further evaluation, care and/or treatment",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "HIV Prevention Trials Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 447,
      "start_date": "2021-06-02",
      "completion_date": "2024-12-17",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • The Bronx, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04804072"
    },
    {
      "nct_id": "NCT07342881",
      "title": "Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis B Infection"
      ],
      "interventions": [
        {
          "name": "Pevifoscorvir Sodium (ALG-000184)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aligos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-03-10",
      "completion_date": "2026-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07342881"
    },
    {
      "nct_id": "NCT03393754",
      "title": "Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B Vaccines"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VBI Vaccines Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1607,
      "start_date": "2017-12-13",
      "completion_date": "2019-04-08",
      "has_results": true,
      "last_update_posted_date": "2020-07-17",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Anaheim, California • DeLand, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03393754"
    },
    {
      "nct_id": "NCT02263079",
      "title": "A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediatric Immuno-Tolerant Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Entecavir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alfa-2A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 62,
      "start_date": "2014-06-16",
      "completion_date": "2020-01-29",
      "has_results": true,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 3,
      "location_summary": "Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263079"
    },
    {
      "nct_id": "NCT00124241",
      "title": "An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "telbivudine",
          "type": "DRUG"
        },
        {
          "name": "lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2015-05-12",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00124241"
    },
    {
      "nct_id": "NCT00096785",
      "title": "Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B",
        "Chronic Disease"
      ],
      "interventions": [
        {
          "name": "entecavir",
          "type": "DRUG"
        },
        {
          "name": "adefovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2004-12",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2010-08-10",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 11,
      "location_summary": "San Diego, California • San Francisco, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "North Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096785"
    },
    {
      "nct_id": "NCT04843852",
      "title": "TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B",
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-10-16",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-22T08:12:46.690Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843852"
    }
  ]
}